CD14 and lung cancer: There was no significant change in the proportion of CD3+ T cells and CD3-CD16+CD56+ NK cells (P =0.1427, P= 0.4708) in the best immune status groups of lung cancer compared with the healthy groups, and the p-value of the proportion of CD14+ monocytes was 0.0053.